Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. (Israel) is dated August 6, 2024. The document serves as a Notice of Annual General Meeting of Shareholders scheduled for September 17, 2024, at the company's offices in Tel Aviv. The filing incorporates the notice by reference into various Registration Statements on Forms S-8 and F-3.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document notes that shareholders will have the opportunity to review financial statements for the fiscal year ended December 31, 2023, at the meeting, but the figures themselves are not included in this text.
Material Changes
No material financial changes or operational updates are detailed in this filing. The document focuses exclusively on corporate governance matters and the upcoming shareholder meeting agenda.
Guidance, Outlook, and Corporate Actions
The filing outlines five key proposals for shareholder approval at the Annual General Meeting:
- Appointment of Kesselman & Kesselman (PricewaterhouseCoopers International Limited) as auditors for 2024.
- Re-election of directors Eric Swenden and Ofer Tsimchi, and election of Dr. Roni Mamluk to the Board of Directors for a three-year term.
- Approval of Restricted Share Unit (RSU) grants to non-executive directors (1 ADS each).
- Approval of RSU grants to CEO and Chairman Dror Ben-Asher.
- Approval of RSU grants to Chief Commercial Officer and Director Rick D. Scruggs.
The Board of Directors recommends voting "FOR" all proposals. Shareholders of record as of August 6, 2024, are entitled to vote. The filing does not contain specific forward-looking guidance on product development or financial outlook.
Key Facts for Investor Verification
- Verify the date and location of the Annual General Meeting: September 17, 2024, in Tel Aviv.
- Confirm the record date for voting eligibility: August 6, 2024.
- Review the specific terms of the proposed RSU grants to executives and directors, as these impact equity dilution.
- Check the company website or subsequent filings for the actual financial statements for the year ended December 31, 2023, which are referenced but not included here.
- Note the deadline for submitting Position Statements regarding agenda items: September 7, 2024.